Dr Gian P. Camenisch, Novartis Institute of Biomedical Research (NIBR), Basel
Assessing Class-Dependant Drug Development Risk using a novel Compound Categorization
Approach.
Start Date
21.11.2018 - 17:00
Event End
21.11.2018 - 18:00
Location
Universität Basel, Pharmazentrum
Assessing Class-Dependant Drug Development Risk using a novel Compound Categorization
Approach.